Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to investigate the efficacy of Atomoxetine (ATMX) in
the treatments of adolescent and young adult Attention Deficit Hyperactivity Disorder (ADHD)
with comorbid Substance Use Disorder (SUD). The secondary objective of the study is to
determine the efficacy of ATMX in preventing SUD relapse. As previous pre-clinical work has
demonstrated that ATMX has led to significant improvement in ADHD in children and lacks abuse
liability, the investigators hypothesize that ATMX will be efficacious in treating ADHD in
adolescents and young adults with SUD, and that ATMX will also be efficacious in preventing
SUD relapse.
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)